DexCom, Inc. (NASDAQ:DXCM) Stock Position Lifted by Park Place Capital Corp

Park Place Capital Corp grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3,516.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 868 shares of the medical device company’s stock after acquiring an additional 844 shares during the period. Park Place Capital Corp’s holdings in DexCom were worth $68,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. raised its stake in DexCom by 4.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after purchasing an additional 162 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of DexCom by 1.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares during the last quarter. Riverview Trust Co grew its holdings in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the last quarter. Finally, Koa Wealth Management LLC grew its holdings in shares of DexCom by 7.7% in the 3rd quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock worth $253,000 after purchasing an additional 270 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $87.09 on Thursday. The company has a market capitalization of $34.02 billion, a P/E ratio of 52.15, a price-to-earnings-growth ratio of 2.21 and a beta of 1.12. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company’s 50 day moving average price is $78.70 and its two-hundred day moving average price is $77.37. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DXCM shares. Canaccord Genuity Group upped their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.